{"page_content": "Sources  Company \ninformation  \nZealand Pharma A/S\nSydmarken 112860 S\u00f8borgDenmark\nCVR no.: 20 04 50 78Tel: +45 88 77 36 00\nFax: +45 88 77 38 98\nZealand Pharma U.S., Inc.\n44 Farnsworth Street 4th FloorBoston, MA 02210 \ninfo@zealandpharma.com\nwww.zealandpharma.com\nEstablished\n1998\nRegistered office\nGladsaxe\nAuditors\nEY Godkendt RevisionspartnerselskabCVR no.: 30 70 02 282021 Achievements\n\u00b9 (Partner ed with Alexion (AstraZeneca))\nPeptide platform\n\u00b9  ( This includes Lixisenatide licensed to Sanofi and sold under the mark Lyxumia\u00ae in the EU \nand Adlyxin\u00ae in the US as well as Dasiglucagon)\n\u00b2\n K\numanyika S et al., N Engl J Med (2020) 383:2197-2200\nZealand Pharma Pipeline\n\u00b9 Licensed to Boehringer Ingelheim. \n\u00b2\n Licensed to AstraZ\neneca.\nSevere Hypoglycemia in diabetes/Zegalouge\n\u00b9  Interna tional Hypoglycemia Study Group. Glucose concentrations of less than 3.0 \nmmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Published in both Diabetes Care 2017 Jan; 40(1): 155-157 and Diabetologia 2017;6-:3-6.\n\u00b2\n  Siyed Y\n. Dasiglucagon in severe hypoglycemia: a profile of its use. Drugs & Therapy Per-\nspectives 2022. https://doi.org/10.1007/s40267-022-00894-x\n\u00b3\n  Z\negalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021\nCHI\n\u00b9  Congenital Hyperinsulinism Interna tional. Available at: http://congenitalhi.org\n\u00b2\n  De Leon et al. Na\nt Clin Pract Endocrinol Metab 2007;3:57-68\n\u00b3\n  Y\norifuji et al. Pediatrics International 2014;56:467\n\u2074\n  Eljamel et al. Orphanet Journal o\nf Rare Diseases 2018;13:123Type 1 diabetes\n\u00b9   Hypoglycemia in the Diabetes Contr ol and Complications Trial. The Diabetes Control and \nComplications Trial Research Group. Diabetes. 1997;46:271-286; \n\u00b2\n  Abraham et al. Pedia\ntr Diabetes. 2018;19(Suppl. 27):178-192; \n\u00b3\n  Interna\ntional Hypoglycaemia Study Group; Diabetes Care. 2015;38:1583-1591; \n\u2074\n Edridge et al. PloS ONE. 2015:10:e0126427\n.\n\u2075\n  Chr\nonic usage of other 2nd generation products is likely hindered by DMSO additive and \ninhalation format, respectively\nObesity / Type 2 diabetes\n\u00b9 K umanyika S et al., N Engl J Med (2020) 383:2197-2200\nShort Bowel Syndrome (SBS)\n\u00b9 Jeppesen P . Expert Opinion on Orphan Drugs (2013) 1(7):515-525\nCorporate Matters\n\u00b9 The Nomina tion Committee is a sub-set of the board.\n\u00b2\n Formaliz\ned of April 2021.\n\u00b3\n Resigned fr\nom company and as employee elected board member in September 2021\n\u2074\n Joined the boar\nd as of Gertrud Koefoed Rasmussen\u2019s resignation in September 2021\nBoard of Directors and Corporate Management\n\u00b9 Resigned in 2006 and r e-elected in 2007.\n\u00b2\n Employee-elected boar\nd members are elected for a period of four years.121\nZealand Pharma  \u221e  Annual Report 2021Other \u2013 Sources - Company info", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 120, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}